Abstract

BackgroundWe aimed to determine the reliability and validity of a hepatitis symptom inventory and to identify predictors of hepatitis C (HCV) treatment initiation in a cohort of HIV-infected patients.MethodsProspective clinic based study that enrolled patients referred for HCV therapy consideration. A hepatitis symptom inventory and the Center for Epidemiologic Studies Depression Scale (CES-D) were administered to HIV/HCV individuals. The symptom inventory was factor analyzed and subscale reliability estimated with Cronbach's alpha. Predictive validity was evaluated using generalized estimating equations (GEE). Predictors of HCV treatment were identified using logistic regression.ResultsBetween April 2008 to July 2010, 126 HIV/HCV co-infected patients were enrolled in the study. Factor analysis using data from 126 patients yielded a three-factor structure explaining 60% of the variance for the inventory. Factor 1 (neuropsychiatric symptoms) had 14 items, factor 2 (somatic symptoms) had eleven items, and factor 3 (sleep symptoms) had two items, explaining 28%, 22% and 11% of the variance, respectively. The three factor subscales demonstrated high intrinsic consistency reliability. GEE modeling of the 32 patients who initiated HCV therapy showed that patients developed worsening neuropsychiatric and somatic symptoms following HCV therapy with stable sleep symptoms. Bivariate analyses identified the following as predictors of HCV therapy initiation: lower HIV log10 RNA, lower scores for neuropsychiatric, somatic and sleep symptoms, lower CES-D scores and white ethnicity. In stepwise multiple logistic regression analysis, low neuropsychiatric symptom score was the strongest independent predictor of HCV therapy initiation and HIV log10 RNA was inversely associated with a decision to initiate HCV treatment.ConclusionsA 41-item hepatitis-related symptom inventory was found to have a clinically meaningful 3-factor structure with excellent internal consistency reliability and predictive validity. In adjusted analysis, low neuropsychiatric symptom scores and controlled HIV infection were independent predictors of HCV treatment initiation. The usefulness of the HCV symptom inventory in monitoring HCV treatment should be evaluated prospectively.

Highlights

  • We aimed to determine the reliability and validity of a hepatitis symptom inventory and to identify predictors of hepatitis C (HCV) treatment initiation in a cohort of HIV-infected patients

  • We set out an exploratory analysis to evaluate a HCV symptom inventory in a population of HIV-coinfected patients referred for HCV treatment

  • Between 1 April 2008 and 31 July 2010, 193 HIVinfected individuals naïve for HCV therapy were referred to our clinic for assessment of HCV treatment eligibility

Read more

Summary

Introduction

We aimed to determine the reliability and validity of a hepatitis symptom inventory and to identify predictors of hepatitis C (HCV) treatment initiation in a cohort of HIV-infected patients. Current standard protocols for the assessment of HCV treatment eligibility incorporate routine screening of depression [13], HCV/HIV patients often have multiple nonspecific symptoms referred as ‘somatic symptoms’ that may or not be related to hidden depression [12]. There is lack of standardization for assessment of these symptoms among HCV/HIV patients being considered for HCV treatment initiation. We set out an exploratory analysis to evaluate a HCV symptom inventory in a population of HIV-coinfected patients referred for HCV treatment. The aims of this study were: 1) to determine the reliability and validity of a HCV symptom inventory and 2) to identify predictors of HCV treatment initiation in a cohort of HIV patients referred for HCV treatment

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call